Subsidiary of CSPC Innovation to Present SYS6043 Phase I Data at 2026 ASCO Annual Meeting

Stock News06-02

CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will present Phase I clinical research data for SYS6043 in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago.

According to the announcement, SYS6043 is a novel B7-H3-targeting antibody-drug conjugate (ADC). The research findings indicate that SYS6043 holds promise as a treatment option for multiple tumor types. The therapy demonstrated favorable anti-tumor activity in patients across several cancer indications.

In the study involving 533 efficacy-evaluable patients, the objective response rate (ORR) was 41.8%, the disease control rate (DCR) was 81.4%, and the median duration of response (mDoR) was 6.9 months.

The company is currently advancing related research for ovarian cancer, breast cancer, and small cell lung cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156844864?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-02 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156844864","market":"nz","top_or_hot":-1,"title":"Subsidiary of CSPC Innovation to Present SYS6043 Phase I Data at 2026 ASCO Annual Meeting","media":"Stock News","content":"<p>CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will present Phase I clinical research data for SYS6043 in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago.<br><br>According to the announcement, SYS6043 is a novel B7-H3-targeting antibody-drug conjugate (ADC). The research findings indicate that SYS6043 holds promise as a treatment option for multiple tumor types. The therapy demonstrated favorable anti-tumor activity in patients across several cancer indications.<br><br>In the study involving 533 efficacy-evaluable patients, the objective response rate (ORR) was 41.8%, the disease control rate (DCR) was 81.4%, and the median duration of response (mDoR) was 6.9 months.<br><br>The company is currently advancing related research for ovarian cancer, breast cancer, and small cell lung cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Subsidiary of CSPC Innovation to Present SYS6043 Phase I Data at 2026 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSubsidiary of CSPC Innovation to Present SYS6043 Phase I Data at 2026 ASCO Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-02 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will present Phase I clinical research data for SYS6043 in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago.<br><br>According to the announcement, SYS6043 is a novel B7-H3-targeting antibody-drug conjugate (ADC). The research findings indicate that SYS6043 holds promise as a treatment option for multiple tumor types. The therapy demonstrated favorable anti-tumor activity in patients across several cancer indications.<br><br>In the study involving 533 efficacy-evaluable patients, the objective response rate (ORR) was 41.8%, the disease control rate (DCR) was 81.4%, and the median duration of response (mDoR) was 6.9 months.<br><br>The company is currently advancing related research for ovarian cancer, breast cancer, and small cell lung cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300765","symbol_name":"石药创新","start_time":0,"source_url":"","article_id":"1156844864","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156844864","pubTimestamp":1780387821,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BK0226":"食品制造"},"translate_title":"石药集团创新子公司将在2026年ASCO年会上展示SYS6043一期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1},"content_text":"CSPC Innovation Pharmaceutical Co., Ltd. (ASX equivalent: 300765) has announced that its controlling subsidiary, Shijiazhuang Yiling Pharmaceutical Co., Ltd. (referred to as Yiling Biopharma), will present Phase I clinical research data for SYS6043 in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for May 29 to June 2, 2026, in Chicago.According to the announcement, SYS6043 is a novel B7-H3-targeting antibody-drug conjugate (ADC). The research findings indicate that SYS6043 holds promise as a treatment option for multiple tumor types. The therapy demonstrated favorable anti-tumor activity in patients across several cancer indications.In the study involving 533 efficacy-evaluable patients, the objective response rate (ORR) was 41.8%, the disease control rate (DCR) was 81.4%, and the median duration of response (mDoR) was 6.9 months.The company is currently advancing related research for ovarian cancer, breast cancer, and small cell lung cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156844864","isCrawlerRequest":true}